PubHealth.info® (An Information Portal on Public Health Issues / Topics, Presented in Collaboration with PakMed Biomedical Solutions)

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]


Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

Here you can find more than 42,000 article titles on "Contraception (Birth Control) and Family Planning" , along with their abstracts and bibliographic information (one of the world's largest collections of article titles on this topic), mentioned in various lists that are sorted/arranged according to the years of publication. You can view the bibliographic details and abstracts of these articles, by clicking the title of your required article. To view other lists of articles in the same category "Contraception (Birth Control) and Family Planning", please visit "Category Lists Homepage" or select a list from the following dropdown list of article titles.

 

List 82: Articles 40501-41000 (500 Articles)

To view other lists in the same category, please VISIT LISTS HOME PAGE or select a list from the above dropdown list of article titles
  1. The oral contraceptives in clinical practice.
  2. Oral contraceptives, lipoproteins, and lipid transport.
  3. Oral contraceptives, surgery and prolonged bed rest.
  4. Oral contraceptives.
  5. Oral contraceptives.
  6. Oral contraceptives.
  7. Oral contraceptives: the past and future.
  8. Oral contraceptives: long-term use produces fine structural changes in liver mitochondria.
  9. Oral contraceptives: safety and complications.
  10. Oral contraceptives: their side effects and ophthalmological manifestations.
  11. Oral contraceptives: which one and for whom?
  12. Organization of the 1969 Institute (Medical education and family planning)
  13. The Orleans parish family planning demonstration program: a description of the first year.
  14. Other medical birth control methods.
  15. Our experience with oral contraceptives.
  16. Our most explosive sex education issue: birth control.
  17. Ovanon, new sequential oral contraceptive. Preliminary report. [Ovanon, nuevo anticonceptive oral secuencial. Reporte preliminar.]
  18. Ovarian morphogensis in the first spontaneous cycles after prolonged oral contraception.
  19. Ovarian morphology during and after use of oral contraceptives. [Ovariets morfologi under og etter bruk av peroral antikonsepsjon.]
  20. Ovulation following "ovariostatic" treatment with steroid contraceptives. [Ovulazione dopo sospensione di un trattamento "ovariostatico" con contracettivi steroidei.]
  21. Pakistan's family planning programme.
  22. Panama. (Family planning)
  23. Papua and New Guinea. (Family Planning)
  24. Parenteral medroxyprogesterone as a contraceptive agent.
  25. Patients knowledge, attitude and behaviour. (Contraception in New Delhi)
  26. Patterns of contraceptive use among clients of the Barbados Family Planning Association.
  27. Patterns of family planning.
  28. Peace Corps to work with family planning.
  29. Perceptions of contraceptive practice by others: effects on acceptance.
  30. Personal factors. (Contraceptive methods.)
  31. In perspective: the birth control revolution,.
  32. Peru. (Family Planning)
  33. A philosophy and some principles proposed for family planning programs.
  34. Physiological and pathological influences on serum monoamine oxidase level: effect of age, sex, contraceptive steroids and diabetes mellitus.
  35. Physiological bases of family planning. A. Physiological bases of reproduction related to conception control.
  36. A pill-a-month contraceptive.
  37. Pituitary gonadotropin effects of contraceptive steroids.
  38. Place of male sterilization in Pakistan's family planning programme (1965-1970)
  39. Planned Parenthood affiliates and educational activities.
  40. Planned parenthood concepts for public health nurses: evaluation of some aspects of an in-service program.
  41. Planning for community-wide family planning services.
  42. Plasma aminoacids and oral contraceptives.
  43. Plasma lipid and lipoprotein alterations during oral contraceptive administration.
  44. Plasma protein changes induced by sequential type of contraceptive steroid pills.
  45. Plasma proteins after continuous, oral use of a progestogen--chlormadinone acetate--as a contraceptive.
  46. Plasma renin activity and aldosterone excretion rate in normal subjects. II. Effect of oral contraceptive agents.
  47. Platelet adhesiveness and lipoprotein lipase activity in controls and in subjects taking oral contraceptives.
  48. Platelet aggregation during oral contraception.
  49. Population and family planning programs: a factbook.
  50. Population and family planning.
  51. Population policy for Americans: is the government being misled? Family Planning and Public Policy: Who is Misleading Whom?
  52. Population: more than family planning.
  53. Post-coital contraception with dienoestrol.
  54. Post-coital oral contraception.
  55. Post-coital oral contraception. (Abstract only)
  56. Postpartum approach to family planning: program results and future implications.
  57. Practical steps in initiating family planning services.
  58. Pregnancy following oral contraceptive therapy.
  59. Pregnancy outreach in family planning.
  60. Preliminary evaluation of four oral contraceptives containing only progestogens.
  61. A preliminary report on the use of a long acting contraceptive. (Abstract only)
  62. The present status of the abortion battle and family planning in Yugoslavia. [Der gegenwartige Stand der Abortusbekampfung und Familienplanung in der SFR Jugoslawien.]
  63. Prevalence rates of uterine cervical carcinoma in situ for women using the diaphragm or contraceptive oral steroids.
  64. The problem of contraception.
  65. The problem of family planning.
  66. The problem of possible effects of oral contraceptives on cancer of the breast.
  67. Problems and attitudes in family planning. Summary of main findings.
  68. Problems of contraception in Afghanistan. [Probleme der Konzeptionsverhutung in Afghanistan.]
  69. Problems on family planning in Indonesia. (Abstract only)
  70. Problems, attitudes and programmes of family planning in Jamaica.
  71. Progesterone oral contraception and blood coagulation.
  72. Progestogen-only oral contraceptives.
  73. Prognosis for the development of new chemical birth-control agents.
  74. Programmed Instruction: an effective technique for family planning training.
  75. Proposal for a physiologically-based birth control method. [Proposta di un metodo per il controllo delle nascite su basi fisiologich e.]
  76. Psychiatric aspects of failures with oral contraceptives.
  77. Psychiatric aspects of oral contraceptives.
  78. Psychiatric aspects of oral contraceptives.
  79. Psychiatric aspects of oral contraceptives.
  80. Psychiatric aspects or oral contraceptives.
  81. The psychical and sexual adaptation of oral contraceptive users.
  82. Psychodynamics on the side effects of oral contraceptives. [Zur Psychodynamik der Nebenwirkungen von oralen Kontrazeptiva.]
  83. Psychologic considerations for the evaluation of long-term use of oral contraceptives.
  84. Psychosis associated with the use of oral contraceptive agents.
  85. Psychosomatic aspects of family planning. [Aspectos sicosomaticos de la planificacion familiar.]
  86. Puerperal thromboembolism.(Oral contraception and superficial thrombophlebitis)
  87. Puerto Rico. (Family planning)
  88. Questions and answers about the charge of "genocide" as it relates to Planned Parenthood-World Population, its affiliates, and the provision and expansion of private and publicly sponsored family planning programs in the U.S.
  89. A quick glance at four years of intrauterine contraception. [Regard rapide sur quatre annees de contraception intrauterine.]
  90. Quinestrol: a potential contraceptive agent.
  91. Radiographic aspects of perforated intrauterine contraceptive devices.
  92. A re-examination of the process by which people adopt family planning.
  93. Recent trends in attitudes toward fertility control and in the practice of contraception in the United States.
  94. Recent trends in attitudes toward fertility control and in the practice of contraception in the United States.
  95. Regional enteritis, superior mesenteric vein thrombosis, common iliac thromboembolism: possible association with oral contraceptives.
  96. Relation between oral contraceptive hormones and blood clotting.
  97. Relationship between the oral contraceptive and folic acid metabolism: serum folate concentrations.
  98. Relationship of administered estrogen, progesterone, and oral contraceptives to cancer of the breast and genital organs of women.
  99. The relationship of Budd-Chiari syndrome to oral contraceptives and trauma.
  100. Relationships between family planning and maternal and child health.
  101. Relative fecundability of users and nonusers of contraception.
  102. Report of a study using long acting injectable contraceptive done by the Family Planning and Population Board on 750 women in Singapore.
  103. Report of the expert group on assessment of acceptance and use-effectiveness of family planning methods.
  104. Report of the Expert Group on Assessment of Acceptance and Use-Effectiveness of Family Planning Methods. (Meeting held at Bangkok, Thailand, 11-21 June 1968.)
  105. Report of the Task Force on Thromboembolic Disorders: thromboembolism and oral contraceptives: an epidemiological case-control study.
  106. Report on a new intrauterine contraceptive device. (Abstract only)
  107. Report on Japan's experience. (Family Planning)
  108. Report on new acceptors of family planning. Ceylon First Quarter 1969.
  109. Report on new acceptors of family planning. Ceylon second quarter 1969.
  110. Report on the use of oral contraceptives in the Singapore National Program: a study of continuation rates of oral contraception based on 18 month's experience.
  111. Report: task force on family planning, Djakarta, June 19-July 31, 1969.
  112. Reports on side effects of therapy with drugs and peroral contraceptives during the period 1 May 1968-1 May 1969. [Indberetninger om bivirkninger under behandling med laegemidler og perorale antikonceptionsmidler i perioden 1. maj 1968-1. maj 1969.]
  113. Responses of young rats to an oral contraceptive fed with varying levels of pyridoxine.
  114. Results of a family planning program in the western area of the city of Santiago.
  115. Reunion. (Family planning)
  116. Review of arterial thrombosis in association with oral contraceptives.
  117. A review of carbohydrate metabolism and the oral contraceptives.
  118. A review of findings of selected KAP studies in family planning: some implications for mass media campaigns.
  119. Rheumatic symptoms and oral contraceptives.
  120. Rheumatic symptoms and serological abnormalities induced by oral contraceptives.
  121. Risks of oral contraceptives. [Risiken oraler Kontrazeption.]
  122. Role of advisory services (in family planning programs)
  123. The role of blood platelets in thrombosis in relation to the effects of contraceptive steroids on platelet function.
  124. Role of cervical mucus in contraception with the continuous chlormadinone acetate method.
  125. The role of family planning in the primary prevention of mental illness.
  126. The role of oral contraceptive agents in cerebral arterial occlusion.
  127. Role of sterilization operations in family planning.
  128. The role of the medical school in family planning.
  129. The role of the nurse and midwife in family planning services.
  130. Rx for birth control.
  131. Ryukyu Islands (Okinawa) (Family planning)
  132. San Francisco's teen clinic: meeting the sex education and birth control needs of the sexually active schoolgirl.
  133. Sarawak. (Family planning)
  134. Selected additional references on family planning.
  135. Selected case reports from U.S. universities currently involved in family planning programs.
  136. Semen quality in relation to infertility and to contraception.
  137. Sequential approach to oral contraceptive therapy.
  138. Sequential oral contraception and clotting factors.
  139. Sequential oral contraceptive and breakthrough bleeding.
  140. Sequential oral contraceptives. Comparative study. [Contraceptivos orais sequenciais. Estudo comparativo.]
  141. Serious complications of intrauterine contraceptive devices.
  142. The serum alanine aminotransferase activity and the two-hour sulphobromophthalein retention test during daily low-dose gestagen oral contraceptive treatment.
  143. Serum copper levels in normal subjects receiving an oral contraceptive.
  144. Serum enzyme activity and bromsulphalein retention during use of oral contraceptives.
  145. Serum insulin and growth hormone responses to arginine infusion before and during treatment with contraceptive steroids.
  146. Serum lipid levels during oral contraceptive and glucocorticoid administration.
  147. Serum luteinizing and follicle stimulating hormone levels during sequential and nonsequential contraceptive treatment of eugonadal women.
  148. Serum vitamin B-12 binding capacity and oral contraceptive hormones.
  149. Several ideas concerning family planning.
  150. Sex and contraception in Sherupur: family planning in a North Indian village.
  151. Sex and marital counseling in family planning.
  152. Sex education and family planning.
  153. A short term study of various methods of birth control and their relation to age, parity and income.
  154. The side effects of oral contraceptives.
  155. Side-effects of oral contraceptives.
  156. Side-effects of oral contraceptives. (Letter to the editor)
  157. Singapore: the use of oral contraceptives in the national program.
  158. Smoking habits of oral contraceptive users.
  159. Social and demographic characteristics of family planning clients in Barbados.
  160. Social and psychological study of birth control in 100 middle-class families. [Estudio psicosocial de la regulacion de la natalidad en 100 familias de la clase media.]
  161. Social aspects of contraception. Comparative studies of European and Latin American conditions. [Soziale Aspekte bei der Antikonzeption. Eine vergleichende Untersuchung zwischen europaischen und lateinamerikanischen Verhaltnissen.]
  162. Sociomedical studies on 60,000 applicants for family planning.
  163. Some aspects of oral contraceptives and married women.
  164. Some aspects of postpartum physiology relating to the basal temperature curve. Applications for birth control. Statistical study of 750 cases. [Quelques aspects de la physiologie du post-partum. Apports de la courbe thermique basale. Applications a la regulation des naissances. Etude statistique sur 750 cas.]
  165. Some effects of contraceptive steroids on hepatic function in normal women and in patients with acquired and inheritable defects in hepatic excretory function.
  166. Some effects of oral contraceptives on carbohydrate metabolism.
  167. Some information concerning a small pilot project in family planning in Kiara and Pondok-Pinang.
  168. Some potential side effects of hormonal contraceptives. [Ueber einzelne potentielle Nebenwirkungen der hormonalen Kontrazeptiva.]
  169. Some principles in family planning programs.
  170. Special aspects of family planning in Africa. [Besonderheiten der Familienplanung in Afrika.]
  171. Specifications for a national system for family planning improvement.
  172. St. Kitts-Nevis-Anguilla (Leeward Islands) (Family planning)
  173. St. Lucia (Family planning)
  174. St. Vincent (Family planning)
  175. A statewide family planning program: evaluation by continuous computer monitoring.
  176. Statistical evaluation of contraceptive methods: use-effectiveness and extended use-effectiveness.
  177. Status of family planning in Peru.
  178. Studies of mini-micro contraceptive doses of a new progestogen: a preliminary report.
  179. Studies of venous blood pyruvate and lactate levels during oral and intravenous glucose tolerance tests in women receiving oral contraceptives.
  180. Studies on intrauterine contraceptive device of different material (II) endometrial histology.
  181. Studies on intrauterine contraceptive devices: 4. The position of IUD in the cavity of uterus and nidation of fertilized ova.
  182. Studies on the antifertility effect and metabolism of a new postcoital oral contraceptive, 2-methyl-3-ethyl-4-phenyl-delta 4-cyclo-hexene carboxylic acid, sodium salt (ORF-4563)
  183. Studies on the mechanism of hypertriglyceridemia induced by oral contraceptives.
  184. Studies on the mechanism of increased plasma triglyceride levels induced by oral contraceptives.
  185. A study in the acceptability and effectiveness of intrauterine contraception in relation to socio-medical variables.
  186. Study of a case of arterial hypertension imputable to intake of an estrogen-progestagen contraceptive. Implication of the renin-angiotensin-aldosterone system. [Etude d'un cas d'hypertension arterielle imputable a la prise d'un contraceptif oestroprogestatif. Implication du systeme renine-angiotensine-aldosterone.]
  187. Study of an injectable progestagen with long term contraceptive effects. Depo-provera 150 and 400 mg. [Etude d'un progestatif injectable de longue duree contraceptif. Depo-provera 150 et 400 mg.]
  188. A study of factors affecting choice of contraceptives.
  189. A study of oral contraceptive users in Bombay.
  190. Study on a method to improve simultaneously vital statistics and family planning among maternity cases.
  191. A study on beliefs and customs in a Lucknow village in relation to certain diseases, menstruation, child birth and family planning.
  192. A study on family planning in a slum community in Pondicherry.
  193. Superficial thrombophlebitis in patients on oral contraceptives.
  194. Suppression of fertility by intrauterine copper and zinc in rabbits: a new approach to intrauterine contraception.
  195. Suriname (Family planning)
  196. Switching pills (The difficulties and hazards of switching oral contraceptives.)
  197. Synopsis of a proposal for a family planning bond.
  198. Systematic investigations on the influence of a contraceptive on some biochemical parameters of fat and carbohydrate metabolism.
  199. Taiwan's family planning in charts.

     

  200. Talking upstairs. (Discussion between students and faculty on dispensing of oral contraceptives by college health centers.)
  201. Technical notes for chapter 8 (Intentions to accept family planning)
  202. The teenager and contraception.
  203. The testing and evaluation of contraceptive methods.
  204. Testing of contraceptive methods: progestogen only - chlormadinone acetate - in continuous daily dosages. [Antikonceptionsmedelsprovning: rent gestagen - klomadinonacetat - i kontin uerlig, lag dos.]
  205. Thailand. (Family planning)
  206. Thailand: monitoring the commercial distribution of oral contraceptives.
  207. Thailand: using family planning acceptors to recruit new cases.
  208. Thermal patterns of the female breast. (Oral contraceptives)
  209. The thread of decency: a sociological interpretation of the respect dimension in family planning clinics.
  210. Three years of Pakistan's new National Family-Planning Programme.
  211. Thromboembolic disorders and oral contraceptives (author's response)
  212. Thromboembolic disorders and oral contraceptives.
  213. Thromboembolic disorders and oral contraceptives.
  214. Thromboembolic disorders and oral contraceptives. (Letter to the editor)
  215. Thromboembolism and contraceptive medication: incidence and mechanism.
  216. Thrombophlebitis in the course of the use of oral contraceptives. [Tromboflebitis u toku primjene oralne kontracepcije.]
  217. Thyroid function and oral contraceptives.
  218. Time series of growth in use of oral contraception and the differential diffusion of oral anovulents.
  219. Time series of growth in use of oral contraception and the differential diffusion of oral anovulents.
  220. Tolerance of intrauterine contraceptive devices.
  221. Tonga. (Family Planning)
  222. Topics in clinical medicine: the liver and oral contraceptives.
  223. Toward a master plan for family planning communication.
  224. Training and performance of paramedical personnel in the Pakistan family planning programme.
  225. Training and performance of paramedical personnel in the Pakistan Family Planning Programme. (Abstract only)
  226. Training for family planning counseling: the seminary's role.
  227. A training program for supervisory workers in local family planning programs.
  228. Training strategies for Latin American family planning programs. [Adiestramiento de personal adscrito a programas latinoamericanos de planificacion de la familia.]
  229. Tubal ligation as part of family planning in India.
  230. Tunisian legislation and contraception. [Legislation tunisienne et contraception.]
  231. A Turkish experience (Family Planning)
  232. Uganda. (Family planning)
  233. UNESCO's role in the field of population and family planning.
  234. United States universities currently involved in family planning programs.
  235. United States: exploratory studies of Negro family formation--common conceptions about birth control.
  236. United States: information flow and service-oriented feedback in family planning programs.
  237. Urinary estrogens and pregnanediol before and after insertion of an intrauterine contraceptive device.
  238. Urinary excretion of different corticosteroid-metabolites in oral contraception and pregnancy.
  239. Uruguay (Family planning)
  240. Use of an intrauterine contraceptive device in the treatment of uterine synechiae in infertile women. [Die Applikation eines intrauterinen Antikonzeptionspessar bei der Behand lung der Uterus-Synechien infertiler Frauen.]
  241. Use of chlorthalidone in patients under oral contraceptive treatment. [Emprego da clortalidona em pacientes sob tratamento com anticoncepcionais orais.]
  242. Use of drugs and intrauterine devices for birth control.
  243. Use of modified Lippes loop for intrauterine contraception. [Primenenie modifitsirovannoi petli Lippes dlya vnutrimatochnoi kontratseptsii.]
  244. Use of oral contraceptives in developing countries.
  245. Use of oral contraceptives with or without intervals. [Het gebruik van orale contraceptiva met of zonder pauze.]
  246. The use of programmed instruction in family planning training programs: a preliminary report.
  247. Use-effectiveness of intrauterine contraception as a problem in competing risks.
  248. USSR picks IUD over the pill: Russians launch birth control program to meet demands for contraceptives to curb abortion rate.
  249. Uterine bleeding in amenorrheic rhesus monkeys after intrauterine contraceptive device insertion.
  250. Various practical aspects of ''family planning'' campaigns in developing countries. [O nekotorykh prakticheskikh aspektakh kampanii ''planirovaniya semi'' v razvivayuschikhsya stranakh.]
  251. Vascular occlusion of the colon associated with oral contraception.
  252. Venezuela (Family planning)
  253. Venous effects of oral contraceptives.
  254. Vulvovaginitis and stomatitis due to candida albicans and stellatoides during treatment with oral contraceptives. [Vulvovaginite e stomatite da candida albicans e stellatoidea in corso di somministrazione di anticoncettivi orali.]
  255. What birth control is - and isn't.
  256. What do we know about promoting family planning through the mass media?
  257. What doctors in Turkey think about family planning.
  258. What the churches say about birth control.
  259. What will the future bring in family planning?
  260. What's happening in medicine. Contraceptive efficacy of norgestrel.
  261. Which oral contraceptive should I use?
  262. Who accepts family planning services: demographic and social characteristics of the acceptors.
  263. Why teach family planning?
  264. Working through community institutions for family planning.
  265. World-wide trends in family planning programs.
  266. Zinc and copper levels in pregnant women and those taking oral contraceptives.
  267. Pakistan's administrative approach for a family planning program.
  268. Blood pressure and body weight changes during oral contraceptive treatment.
  269. Clinical and morphological studies on hormonal contraception with the sequential method. [Klinische und morphologische Untersuchungen zur hormonellen Antikonzeption mit der Sequential-Methode.]
  270. Evaluating the success of enrollment efforts in a public family-planning clinic.
  271. Factors affecting Catholic wives' conformity to their church magisterium's position on birth control.
  272. Family planning and population policy: is the "culture of poverty" the new cop-out?
  273. The myth of oral contraceptives in the treatment of infertility.
  274. The role of family planning in the reduction of poverty.
  275. Oral hormone contraception in breast feeding mothers: a comparison between progestin-only, progestin with estrogen metabolites, progestin-estrogen combinations and controls without hormone contraception.
  276. Oral-contraceptive opposition to hypocholesterolaemic action of clofibrate.
  277. The organization of training for family planning.
  278. Organizational procedures in integration of family planning education and maternal and child health service.
  279. Ovanon: a new sequential oral contraceptive.
  280. Overpopulation and contraception.
  281. Family planning and the marketing viewpoint.
  282. Family planning and voluntary workers.
  283. The Family Planning Association of Great Britain.
  284. The Family Planning Association of India: Report of work for 1967-68.
  285. Family planning by nurse-midwives in a rural area.
  286. Family planning communications in Thailand.
  287. Family planning facilities in the Bombay-Thana Industrial Complex: a survey conducted by the Family Planning Association of India for the Co-ordinating Committee for Family Planning of the Indian Merchants' Chamber, Bombay, 1968.
  288. Family planning in Africa.
  289. Family planning in Britain.
  290. Family planning in coal-fields.
  291. Family planning in Greater Colombo.
  292. Family planning in industries.
  293. Family planning in industry: role of Indian Chamber of Commerce, Calcutta.
  294. Family planning in medical education.
  295. Family planning in Pakistan.
  296. Family planning in Singapore.
  297. Family planning in the Bombay-Thana industrial complex.
  298. Family planning in the railways.
  299. Family planning in the Taiwan area of the Republic of China.
  300. Family planning in Uganda.
  301. Family planning Indonesia.
  302. Family planning knowledge, attitudes, and practice in Malaya.
  303. Family planning motivation and communication.
  304. Oral contraceptives and malignant melanoma. (Letter to the editor)
  305. Oral contraceptives and myocardial infarction.
  306. Oral contraceptives and ocular complications. [Contracettivi orali e complicanze oculari.]
  307. Oral contraceptives and patulence of the eustachian tubes.
  308. Oral contraceptives and progressive pulmonary vascular disease.
  309. Oral contraceptives and serum-folate level.
  310. Oral contraceptives and serum-folate levels.
  311. Oral contraceptives and the vital organs.
  312. Oral contraceptives and their management.
  313. Oral contraceptives and thromboembolic disease.
  314. Oral contraceptives and thromboembolic disease.
  315. Oral contraceptives and thromboembolic disease.
  316. Oral contraceptives and thromboembolic disease.
  317. Oral contraceptives and thromboembolic disease.
  318. Oral contraceptives and thromboembolism - once more. [P-piller och trombos - en gang till.]
  319. Oral contraceptives and thromboembolism.
  320. Oral contraceptives and thromboembolism.
  321. Oral contraceptives and thyroid function tests: the role of progestogens.
  322. Oral contraceptives and vascular disease.
  323. Oral contraceptives and venous arterial thromboembolic manifestations: concerning four cases. [Contraceptifs oraux et manifestations thrombo-emboliques veineuses et arterielles: a propos de quatre observations.]
  324. Oral contraceptives during immediate postabortal period.
  325. Oral contraceptives in the treatment of menometrorrhagia of the unique ovary syndrome after unilateral castration. [Les contraceptifs oraux dans le traitement des meno-metrorragies du syndrome de l'ovaire unique apres castration unilaterale.]
  326. Oral contraceptives, pregnancy, and the veins.
  327. Oral contraceptives--choice of product.
  328. Oral contraceptives.
  329. Oral contraceptives.
  330. Oral contraceptives.
  331. United States: public policy and programs in family planning.
  332. Unreliable contraceptive methods.
  333. Urban Indian attitudinal response and behavior related to family planning: possible implications for the mass communication program.
  334. Use and relative effectiveness of various channels of communication in the development of the Korean Family Planning Programme.
  335. The use of a new progestogen, Norgestrel as an oral contraceptive among Filipino women.
  336. Use of Anovlar in gynaecological disorders and contraception.
  337. The use of bicarbonate of soda as a contraceptive agents. [Primenenie bikarbonata natriya v kachestve protivozachatochnovo sredstva.]
  338. Use of immunological and biological techniques to determine hormonal levels in contraception and infertility.
  339. Use of medical-paramedical personnel and traditional midwives in the Pakistan family planning program.
  340. Use of oral and intrauterine contraceptives: an international panel reports.
  341. The use of the radio in support of the family planning program in Hyderabad district of West Pakistan.
  342. Uterine and extra-uterine pregnancies after intrauterine contraception. [Grossesses uterine et extra-uterine apres dispositif intra-uterin.]
  343. Vaginal foam: an alternative to contraception. [Vaginalskum: ett alternativ for antikonception.]
  344. Value issues for social work in family planning: an introductory note.
  345. Vascular occlusion of the colon and oral contraceptives: possible relation.
  346. Vasectomy in family planning.
  347. Venous thromboembolic disease and the use of oral contraceptives. A review of mortality statistics in England and Wales.
  348. Whither IUD? The present and future of intrauterine contraceptives.
  349. Why family planning?: (Demographic and economic aspects with particular reference to Malaysia)
  350. The wider base of the family planning programme.
  351. Withdrawal of oral contraceptives. [Avbruten oral antikonception.]
  352. Within family planning - Korea.
  353. The A.I.D. population and family planning program - goals, scope, and progress.
  354. Acceptability of intrauterine contraceptive device.
  355. Accomplishments and new aspects of contraception.
  356. Acquired subclinical diabetes mellitus in women receiving oral contraceptive agents.
  357. Acute pelvic inflammatory disease in an indigent population: an estimate of its incidence and relationship to methods of contraception.
  358. Address (on family planning in India)
  359. Address (on family planning program)
  360. Address (on family planning program)
  361. Address (on family planning)
  362. Address (on family planning)
  363. Adrenal-pituitary responsiveness during therapy with an oral contraceptive.
  364. The African and the problem of birth control. [l'Africain devant le probleme de la limitation des naissances.]
  365. AID policy on family planning and population growth.
  366. Alterations in ovarian physiology subsequent to oral contraceptive therapy.
  367. Amenorrhea after oral contraceptives.
  368. Amenorrhoea after oral contraceptives.
  369. Amenorrhoea oral contraceptives.
  370. Appendix 3: a guide to family planning.
  371. Assessment of thyroid status in pregnant women and in patients taking oral contraceptives by a free thyroxine index.
  372. Attitude survey of married women regarding family planning at Urban Health Centre, Alambagh, Lucknow.
  373. Attitude, knowledge and practice of family planning techniques among married women in the city of Ibadan.
  374. Attitudes and practice of contraception in Kenya.
  375. The attitudes of the Turkish people regarding family planning and the educational activities in the Turkish Population Planning Program.
  376. Attitudes toward family planning in Turrialba, Costa Rica.
  377. Attitudes towards family planning in East Africa.
  378. Atypical features in breast carcinomas in patients on oral contraceptives.
  379. Awareness sources and stages in the adoption of specific contraceptives.
  380. Barriers in family planning.
  381. Behavior of the arterial and venous blood sugar after oral administration of glucose to a group of subjects treated with oral contraceptives. [Comportamento della curva glicemica artero venosa dopo carico orale di glucosio in un gruppo di soggetti trattati con contracettivi orali.]
  382. The biology and safety of hormonal contraceptive agents.

     

  383. Birth control and regional differentials in the Soviet Union.
  384. Birth control clinics in crowded Puerto Rico.
  385. Birth Control in French Canada. [La limitation des naissances au Canada Francais.]
  386. Birth control, culture, and the poor.
  387. Birth control: U.S. research advances despite Papal edict.
  388. Birth control: the only answer.
  389. Births averted by family planning programs.
  390. The bishops, politics, and birth control.
  391. The black community and family planning.
  392. Breast and reproduction system effects of oral contraceptives.
  393. Budd-Chiari syndrome after oral contraceptives.
  394. Budd-Chiari syndrome after oral contraceptives.
  395. Budd-Chiari syndrome after oral contraceptives.
  396. Budd-Chiari syndrome after oral contraceptives.
  397. Budd-Chiari syndrome after oral contraceptives. (Letter to the editor)
  398. C-FILM: a new local contraceptive.
  399. Caeruloplasmin and green plasma in women taking oral contraceptives, in pregnant women, and in patients with rheumatoid arthritis.
  400. Cambodia (Family planning)
  401. Carbohydrate metabolism and oral contraceptives.
  402. The case for planned parenthood.
  403. Casebook for the intrauterine contraceptive device.
  404. The Catholic community and family planning.
  405. Cervical smears and oral contraception. (Letter)
  406. Ceylon: the Sweden-Ceylon family planning pilot project.
  407. Changes in sexual behavior consequent to use of noncoital procedures of contraception.
  408. Changing methods of contraception.
  409. The changing role and difficulties of voluntary organizations working in the field of family planning.
  410. Chemistry, pharmacology and clinical pharmacology of oral contraceptives.
  411. The Children's Bureau and family planning.
  412. Chlormadinone acetate as an oral contraceptive: clinical results and the incidence of ovulation.
  413. Cholesterol content of menstrual discharge: influence of contraceptives.
  414. A classified international bibliography of family planning research, 1955-68.
  415. Clinical and laboratory experience with a modified low dosage sequential oral contraceptive.
  416. A clinical and pathologic study of endocervical lesions associated with oral contraceptives.
  417. The clinical characteristics of headache during impending cerebral infarction in women taking oral contraceptives.
  418. Clinical evaluation of ethinylestrenol and mestranol as a contraceptive.
  419. A clinical evaluation of intrauterine contraceptive devices.
  420. Clinical evaluation of oral contraceptives.
  421. Clinical experience with the intrauterine contraceptive device in the international field.
  422. Clinical management of complaints associated with the use of oral contraception.
  423. Clinical study of the contraceptive effervescent tablets E-136 (neo sampoon loop tablets) wherein a new surface active agent p-methanylphenylpolyoxyethylene (8,8)ether (TS-88) is used.
  424. A clinical study on a sequential oral contraceptive-Ovisec.
  425. Clinical trial of ethynodiol diacetate in a sequential oral contraceptive.
  426. Clinical trial of ethynodiol diacetate in a sequential oral contraceptive.
  427. Clinical trial of low-dosage contraceptive.
  428. Clinical use of intrauterine contraceptive devices.
  429. Clinical use of norgestrel-ethinyl oestradiol as a contraceptive.
  430. Coitus interruptus: unreliable method of birth control. A statistical study. [Coitus interruptus: controllo delle nascite irrazionale. Sondaggio stattistico.]
  431. Colitis and contraception.
  432. Collection and evaluation of data on contraception.
  433. A college health service should dispense birth control information, services and medications.
  434. A college health service should not dispense birth control devices and medications.
  435. Colonic disorder and oral contraceptives.
  436. Comment (on family planning)
  437. Commercial distribution of contraceptives in developing countries: past, present, and future.
  438. Communication aspects of family planning programme in Pakistan.
  439. Communication in family planning in India with specific reference to Madras State.
  440. Community organization: strategies and techniques for the provision of family planning services.
  441. Comparative study of family planning effects in our industrial and rural communities.
  442. Complications associated with the use of intrauterine contraceptive devices in women of middle and upper socioeconomic class.
  443. Complications of hormonal contraception.
  444. Complications of oral contraceptives.
  445. Conclusions. (Family planning in Ceylon)
  446. Confirmatory data for the relationship between the taking of oral contraceptives and the development of thrombophlebitis and pulmonary embolism.
  447. Continuous low dose progestagen for contraception.
  448. Continuous low-dose progestogen contraception.
  449. Continuous tablet therapy for oral contraception.
  450. Contraception and vaginal infections. [Anticoncezionali e parassitosi vaginali.]
  451. Contraception by the intra-uterine device.
  452. Contraception in marriage.
  453. Contraception in Syria. [De la contraception en Syrie.]
  454. Contraception in undeveloped countries.
  455. Contraception with an injectable progestin: a study of its use in postpartum women.
  456. Contraception: hazardous rhythm.
  457. Contraceptive action of continuous low doses of norgestrel.
  458. Contraceptive behavior in marginal families. [Comportamientos anticonceptivos en la familia marginal.]
  459. Contraceptive effect and physical feeling with the use of a surface active agent, E-136 (Neo-sampoon loop tablets)
  460. Contraceptive methods and material. Current aspects of various medical problems. [Metodiche e mezzi anticoncezionali. Aggiornamento sui vari problemi medici.]
  461. The contraceptive methods.
  462. The contraceptive pill and major arterial emboli in a teen-aged girl.
  463. The contraceptive pill in general practice.
  464. Contraceptive pills.
  465. Contraceptive polyethelene pessaries (author's transl) [Uwagi dotyczace stosowania polietylenowego pesarium antykoncepcyjnego.]
  466. The contraceptive polyp: a diagnostic dilemma.
  467. Contraceptive properties of Stevia rebaudiana.
  468. Contraceptives and Health.
  469. Contraceptives and other steroid drugs: their production from steroidal sapogenins.
  470. The contribution of voluntary family planning associations to African development.
  471. Contribution to the study of motivation toward acceptance or refusal of contraceptive methods. [Contribution a l'etude des motivations de l'acceptation et du refus des methodes anticonceptionnelles.]
  472. Cooperative studies of Sequens, a sequential oral contraceptive agent, in Japan.
  473. Correlates of family planning in eight Indian villages.
  474. Correlates of family planning performance, 1967.
  475. Correlates of IUD termination in a mass family planning program: the first Taiwan IUD follow-up survey.
  476. Cost-benefit analysis of family planning programme.
  477. Current studies in contraception: the use of a long-acting progestogen by injection. (Presented at the Forty-sixth South African Medical Congress, Durban, July 1967)
  478. Cytological study in cases with intrauterine contraceptive device (Lippes' Loop)
  479. Definition of acceptable contraceptive methods.
  480. Demographic facts relative to the politics of family planning in Iran. [Donnes demographiques relatives a la politique de planning familial en Iran.]
  481. Depo-provera as an injectable female contraceptive agent.
  482. Determination of human luteinizing hormone, LH, in plasma by the radioimmunoassay method. Plasma LH level throughout the menstrual cycle in a normal woman, during and after stopping oral contraception. [Dosage plasmatique de l'hormone luteinisante humaine, H.L.H., par la methode radio-immunologique. Taux de L.H. dans de plasma au cours du cycle menstruel de la femme normale, pendant et apres l'arret de contraceptif oral.]
  483. The development of the use of the radio in Pakistan in support of the family planning program during 1968.
  484. Directory of selected training facilities in family planning and allied subjects.
  485. Discussions on the duration of using intrauterine contraceptive pessary and the birth control mechanism.
  486. Duration of use of oral contraception in the United States, 1960-1965.
  487. Early detection of cervical carcinoma by the birth control clinic.
  488. Early post-partum intrauterine contraceptive device insertions.
  489. ECAFE: Working Group on Communications Aspects of Family Planning Programs.
  490. The economic aspects of family planning.
  491. Economic issues in cost-benefit analysis of family planning programs: a report on phase 1 of the Pennsylvania State University USAID Population Research Project: cost-benefit analysis and evaluation of family planning programs, University Park, Pennsylvania, November.
  492. An economic model of family planning and fertility.
  493. The effect of a new low-dosage oral contraceptive pill on lactation.
  494. Effect of a sequential oral contraceptive on plasma insulin and blood glucose levels after 6 months' treatment.
  495. Effect of an intrauterine contraceptive device on biochemical composition of uterine fluid.
  496. Effect of an intrauterine contraceptive device on postpartum involution of the rhesus monkey uterus.
  497. The effect of an oral contraceptive as a preparatory mechanism in the generalized Shwartzman reaction in rabbits.
  498. Effect of contraceptive pills on women in child bearing age and the number of their human offsprings.
  499. Effect of intrauterine contraceptive device upon endometrial exfoliative cytology.
  500. Effect of oral contraceptive agents on platelets and plasma-phospholipids.

To view other lists of the current category of articles, please visit "Category Lists Homepage"


Web PubHealth.info

© Copyrights PubHealth.info®, an information portal on public health. All rights reserved.

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.